This Phase Ib trial evaluated ficlatuzumab, a first-in-class anti-HGF antibody, in combination with cytarabine in acute myeloid leukemia (AML) patients. Among 17 evaluable patients, the overall response rate was 53%, all complete remissions.
[Blood Cancer Discovery]
7992332
{7992332:FRB3UKUT}
apa
50
1
164664
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
